The World Health Organization (WHO) approved a CovavaXTM Coronavirus vaccine made by the Indian Serum Institute under the license of the American company Novavax. It is reported by Associated Press.
A two-component drug has become ninth of the permitted organization for emergency. It is noted that among its advantages – simpler storage conditions. COVAVAXTM is a protein vaccine, created by the older technology, which was used for years to produce other types of vaccines. NOVAVAX from Maryland uses genetic engineering to grow harmless copies of coronavirus spike protein in insect cells. Scientists are removed and cleaned protein, and then an immunostimulating chemical is added.
It is expected that the vaccine will approve a number of countries allowing the entry of the travelers only against coronavirus, and will help increase the level of vaccination in low-income countries. However, the question of how much CovavaxtM is able to help in the fight against the new Omicron-strain coronavirus, remains open, as well as the question of the timing and volume of deliveries.
Earlier, the head of the European Regional Office of the Hans Kejig, the Russian vaccine from Coronavirus “Satellite V” can be approved in the World Health Organization (WHO) in the first quarter of 2022. The director of the Radio Kirill Dmitriev noted that the delays of the approval of the Russian drug are exclusively bureaucratic character.